Cargando…
Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity
The benefit of molecularly-informed therapies in cancer of unknown primary (CUP) is unclear. Here, we use comprehensive molecular characterization by whole genome/exome, transcriptome and methylome analysis in 70 CUP patients to reveal substantial mutational heterogeneity with TP53, MUC16, KRAS, LRP...
Ejemplares similares
-
From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards
por: Perera-Bel, Júlia, et al.
Publicado: (2018) -
Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification
por: Gröschel, Stefan, et al.
Publicado: (2016) -
The landscape of chromothripsis across adult cancer types
por: Voronina, Natalia, et al.
Publicado: (2020) -
Community-driven development of a modified progression-free survival ratio for precision oncology
por: Mock, Andreas, et al.
Publicado: (2019) -
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial
por: Heilig, C.E., et al.
Publicado: (2021)